Xenon Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Okay. Good morning. We'll continue with our next session. I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at the firm. And we'll continue with our next session, which is with Xenon. We're very pleased to have CEO, Ian Mortimer to my immediate left; and CFO, Sherry Aulin, to my far left.
What we'll do is some Q&A with the team. If along the way, anyone has questions in the audience or online, please raise your hand or shoot me an e-mail, and we'll read the questions anonymously over the path -- over the time. But maybe what we'll do, let's start with Ian, with -- maybe with some sort of high-level questions, which is for investors who may not be familiar or new to the Xenon story.
Questions & Answers
Can you maybe give us a quick overview of the company and then maybe a little bit on the sort of basic science that underpins your pipeline and developmental efforts with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |